VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SANA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SANASana Biotechnology, Inc.
$1.85$515M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSANABalance Sheet

Sana Biotechnology, Inc. (SANA) Balance Sheet

8Y historyFree accessUpdated daily

Debt-to-equity of 0.30 on $53.8 million of total debt looks moderate but has risen from 0.63 in 2026Q1 and was 0.29 in 2024Q2, while $140.6 million of goodwill against $41.1 million of cash highlights a thin liquidity cushion and impairment exposure.

Income StatementBalance SheetCash FlowRatios

SANA Balance Sheet

Annual statement

SANA Balance Sheet

Sana Biotechnology, Inc. (SANA) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets132.31M148.68M160.81M213.51M444.44M558.1M384.47M144.26M32.6M
Cash & Short-Term Investments121.73M138.38M152.5M205.19M423.96M551M378.26M138.98M30.63M
Cash Only41.1M71.87M127.57M133.52M176.76M253.03M124.81M80.03M30.63M
Short-Term Investments80.62M66.51M24.93M71.68M247.2M297.97M253.46M58.95M0
Accounts Receivable000000000
Days Sales Outstanding---------
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets3.76M10.29M8.31M8.32M20.47M0000
Total Non-Current Assets243.81M268.21M340.21M351.78M378.28M571.31M345.83M270.93M1.74M
Property, Plant & Equipment43.44M65.22M135.27M145.59M159.4M161.78M109.94M68.81M585K
Fixed Asset Turnover0.00x--------
Goodwill140.63M140.63M140.63M140.63M140.63M140.63M140.63M140.63M0
Intangible Assets59.2M59.2M59.2M59.2M59.2M59.2M59.2M59.2M0
Long-Term Investments000010.05M195.88M33.73M0816K
Other Non-Current Assets551K3.17M5.12M6.37M9.01M13.82M2.33M2.3M336K
Total Assets376.13M416.89M501.02M565.3M822.72M1.13B730.3M415.19M34.33M
Asset Turnover0.00x--------
Asset Growth %-27.22%-16.79%-11.37%-31.29%-27.15%54.65%75.89%1109.31%-
Total Current Liabilities74.88M78.73M45.43M64.49M111.5M99.23M31.45M19.32M1.78M
Accounts Payable1.95M1.67M5.21M4.11M2.86M2.22M2.25M0289K
Days Payables Outstanding270.9647.78----80.85-105.48K
Short-Term Debt000000000
Deferred Revenue (Current)000000000
Other Current Liabilities40.65M51.93M300K23.46M76.59M74.63M14.02M8.09M685K
Current Ratio1.77x1.89x3.54x3.31x3.99x5.62x12.22x7.47x18.26x
Quick Ratio1.77x1.89x3.54x3.31x3.99x5.62x12.22x7.47x18.26x
Cash Conversion Cycle---------
Total Non-Current Liabilities120.88M177.28M205.08M213.31M211.9M301.67M1.12B538.41M45.74M
Long-Term Debt000000000
Capital Lease Obligations163.68M63.92M81.66M90.9M95.86M101.78M68.2M46.36M0
Deferred Tax Liabilities000000000
Other Non-Current Liabilities80.36M113.36M123.42M122.41M116.04M199.89M1.05B492.05M45.74M
Total Liabilities195.76M256.01M250.52M277.79M323.4M400.9M1.15B557.73M47.52M
Total Debt53.84M78.86M94.2M104.1M108.25M110.94M71.91M47.7M0
Net Debt12.74M6.99M-33.37M-29.42M-68.51M-142.09M-52.9M-32.33M-30.63M
Debt / Equity0.30x0.49x0.38x0.36x0.22x0.15x---
Debt / EBITDA-0.41x--------
Net Debt / EBITDA-0.10x--------
Interest Coverage---------
Total Equity180.36M160.88M250.5M287.51M499.31M728.5M-421.18M-142.54M-13.19M
Equity Growth %-60.28%-35.78%-12.87%-42.42%-31.46%272.97%-195.48%-980.85%-
Book Value per Share0.580.641.081.482.654.38-2.25-0.76-0.07
Total Shareholders' Equity180.36M160.88M250.5M287.51M499.31M728.5M-421.18M-142.54M-13.19M
Common Stock30K27K22K20K19K18K2K1K1K
Retained Earnings-1.94B-1.85B-1.6B-1.34B-1.05B-785.36M-429.43M-144.13M-13.25M
Treasury Stock000000000
Accumulated OCI-104K28K14K-60K-4.33M-1.37M30K26K-45.72M
Minority Interest000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Cash runway constraint and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Balance Sheet Shrinking Toward Liquidity Floor

Based on Sana's reported figures, total assets fell from $618.7 million in 2024Q2 to $376.1 million in 2026Q3, a decline of roughly 39 percent that tracks cumulative operating burn rather than any productive asset build.

The contraction in total assets is concentrated in cash and near-cash balances, which declined from $135.0 million to $41.1 million over the period. Equity fell alongside it as accumulated deficit deepened, with retained earnings moving from roughly -$1.5 billion to -$1.9 billion. This pattern suggests the balance sheet is being consumed by clinical spend, and investors should monitor whether the trajectory stabilizes or continues to erode toward a point that forces external financing.

Cash Cushion Thin Against Quarterly Burn

According to recent SEC filings, Sana's cash and equivalents of $41.1 million in 2026Q3 compare against operating cash outflows that have frequently exceeded $30 million per quarter, leaving a cushion of only a few quarters.

The current ratio of 1.77 in 2026Q3 appears adequate on paper, but it is supported largely by short-dated balances that will be drawn down by ongoing R&D commitments. The ratio has moved down from above 5 in 2024 as current liabilities have been maintained while current assets shrank. The liquidity position suggests limited tolerance for trial delays or unexpected cost overruns.

Modest Leverage Masks Equity Erosion

As reported in financial statements, Sana's total debt of $53.8 million against equity of $180.4 million yields a debt-to-equity ratio of 0.30, which looks moderate but was 0.63 as recently as 2026Q1.

The reduction in D/E in the latest quarter reflects a rebound in equity rather than meaningful deleveraging, since total debt also declined from $75.3 million. Total liabilities of $195.8 million remain sizable relative to assets, so creditors hold a substantial claim on a shrinking asset base. Investors should treat the current leverage figure with caution, as it may improve or deteriorate sharply depending on how the next financing is structured.

Asset Base Dominated by Goodwill and Intangibles

Based on Sana's reported figures, goodwill of $140.6 million, unchanged across all ten quarters, represents roughly 37 percent of 2026Q3 total assets, while net PP&E has fallen from $135.3 million to $43.4 million.

The flat goodwill balance across the period suggests it has not been tested for impairment in a way that reflects the decline in market value, which warrants further investigation given the persistent losses. The sharp fall in net PP&E points to either asset write-downs or disposals consistent with the pipeline refocusing noted in recent commentary, rather than a deliberate capital-light shift. Tangible asset backing for the equity is therefore weaker than headline total assets imply.

Goodwill Could Overstate Balance Sheet Strength

Based on reported figures, goodwill of $140.6 million exceeds Sana's total equity of $180.4 million less cash, implying that a meaningful portion of book equity could be eliminated by an impairment charge.

Because goodwill has remained static at $140.6 million through periods of severe share price and cash pressure, the headline equity figure may be less durable than it appears. An impairment would reduce equity without any change to cash burn, potentially tightening covenant or financing terms if any are in place. Investors should monitor future filings for impairment testing disclosures before treating book equity as a reliable measure of loss-absorbing capacity.

SANA — Frequently Asked Questions

Quick answers to the most common questions about buying SANA stock.

What are the total assets of Sana Biotechnology, Inc. (SANA)?

As of 2025, Sana Biotechnology, Inc. (SANA) had total assets of $416.9M including $148.7M in current assets.

How much debt does Sana Biotechnology, Inc. (SANA) have?

Sana Biotechnology, Inc. (SANA) carries total debt of $78.9M, offset by $138.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Sana Biotechnology, Inc.?

Sana Biotechnology, Inc. (SANA) has total shareholders' equity (book value) of $160.9M ($0.64 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Sana Biotechnology, Inc.'s current ratio and liquidity?

Sana Biotechnology, Inc. (SANA) reported a current ratio of 1.89x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.